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Background: Liver disease is an important complication in CF.
Aims: To determine if CFLD is a risk factor for mortality in CF, and which baseline characteristics predict all-cause mortality.
Methods: Irish children with CFLD, and their age and gender matched controls were enrolled at baseline and reviewed after 10 years to determine
which characteristics predict mortality.
Results: 72/84 (85.71%) participants were followed, (mean age Cases 21.71 yrs SD 6.5, CF controls 23.62 SD 5.6, 22 (61%) males), with no
difference in duration of follow-up. Nineteen participants (26.4%) died, 38.9% (14/36) with CFLD and 13.89% (5/36) CF controls (Odds Ratio
(OR) 3.94 95% CI:1.23–12.56 p = 0.005). In logistic regression, liver disease (OR 4.28 95% CI 1.07–17.16) female gender (OR 12.25 95% CI
2.37–63.24), reduced pulmonary function, (OR 5.11 95% CI 1.09–23.81) were each independent risk factors for mortality in CF.
Conclusions: Liver disease is an independent risk factor for mortality in CF.
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in the CFTR gene (cystic fibrosis transmembrane conductance
regulator) leading to defective clearance of secretions from
epithelial surfaces [1–5]. While pulmonary disease still remains
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disease is of increasing importance if we are to further improve
the outcome for patients.
The diagnosis of CFLD is not straightforward and the lack of a
gold standard for the diagnosis has hampered our understanding
of CFLD [2–6]. Many children with CF will develop evidence of
liver abnormalities including raised liver enzymes, abnormalities
on liver ultrasonography or hepatomegaly [2–5]. However, less
than 10% of children with CF have clinically significant liver
disease with portal hypertension [2,4]. The lack of a consistent
definition of CFLD has led to significant disparities in the reportedll rights reserved.
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proposed a classification of CFLD which separates cirrhosis with
or without portal hypertension from other forms of liver disease
such as raised aminotransferases and hepatic steatosis, and the use
of this classification may help improve our understanding of
CFLD [4].
A number of reports have suggested that liver disease is not a
risk factor for mortality in CF [7–9]. However, many of these
studies lack an adequate control group with which to compare
outcome. Liver disease, even in the presence of portal hyperten-
sion is not considered a contraindication to lung transplantation in
CF [10,11], and the outcome following lung transplantation is not
reported to be compromised by the presence of liver disease [12].
Nevertheless, there is emerging evidence, which supports the
hypothesis that liver disease may be a poor prognostic factor in CF
[13–15]
In a national study of CFLD we have shown that children
with clinically significant CFLD are shorter and lighter than their
age and gender matched controls and have worse pulmonary
function [16]. At a 7-year follow-up, while there was no difference
in mortality between CF participants and CF controls, there was
evidence that participants with CFLD had a more severe
phenotype, with reduced nutritional parameters, poorer lung
function and a greater rate of decline in Forced expiratory volume
in 1 sec (FEV1) compared to controls [15]. In the present studywe
continue to follow this cohort 10 years after they participated in
the baseline study to examine differences in all cause mortality
between participants with CFLD and CF controls with no
evidence of liver disease and to identify risk factors for mortality
[17].1. Methods
Persons with CF who participated in the baseline study in
1999–2000 [16] and in the 7 year follow-up [15] were invited to
participate in a review at 10-years. At baseline cases were defined
as any child aged between 5 and 18 years with CF (confirmed by
sweat chloride), who had liver disease with portal hypertension.
Portal hypertension was defined clinically (splenomegaly/
hypersplensim), or ultrasonographically splenomegaly (increased
compared with body-size-appropriate values,) varices, ascites,
reversal of portal vein flow or endoscopically. Controls were
children with CF who had no biochemical, ultrasonographic or
clinical evidence of liver disease. At baseline CF controls were
pair-matched for age and sex with CFLD participants.
Exclusions and losses to follow-up at 10 years were as
follows: 5 cases of CFLD were excluded because they had not
been reviewed by a paediatric hepatologist at baseline; it was
determined on re-examination of their baseline data that their
radiological or clinical assessment was not adequate to support
a diagnosis of portal hypertension [15]. Participants were not
matched for FEV1 at baseline, and there were no a priori exclusion
criteria based on pulmonary function tests at baseline. An FEV1 of
less than 30% predicts mortality within 2 years. On this basis, 3
controls with an FEV1 b 30% at baseline were excluded from
follow-up [15].To review the validity of the baseline findings, the data was
re-analysed without the 8 participants (5 cases and 3 controls)
excluded from the follow-up data. Exclusion of this group of
participants did not alter the findings of the baseline study.
In this follow-up study we used data collected at baseline in
1999–2000 to examine risk factors for mortality after 10 years
follow-up. This included baseline pulmonary function tests
(FEV1 Z scores (Standard Deviation Scores)) anthropometric
data with skin fold measurements, clinical biochemistry, and
gender and liver disease. Baseline data for height, weight, and
body mass index were expressed as centiles and Z scores using
the Centre for Disease Control (CDC) 2000 reference data [18].
Upper arm circumference and skin fold thickness measurements
were calculated as described previously [15,16]. FEV1 was
recorded as absolute values and the reference range described by
Stanojevic et al. [19] (www.growinglungs.org.uk) was used to
calculate centiles and Z scores of FEV1 per cent predicted based
on age height and gender, because Z scores allow a more accurate
comparison of pulmonary function across a range of ages [19,20].
2. Ethical approval
This study was approved by all hospital Research Ethics
Committees providing care for study participants, with the
guidance that eligible participants should not undertake any
extra investigations or hospital visits. Consent was obtained
from participants and/or their parents.
3. Statistical analysis
The baseline study used a paired analysis design to compare
patients with and without CFLD [16]. Losses to follow-up,
exclusions and deaths required un-pairing of the data at
follow-up. The end point for the comparison of the two groups
was death or transplant (liver or lung) referred to as mortality.
Transplant was classified as mortality because in the absence
of a transplant the outcome was death.
Results are presented as median and interquartile range, as most
of the data showed a degree of skewness.Wilcoxon Log-Rank tests
were used to compare groups, and chi-square tests for differences
in proportions. Multiple logistic regression was used to examine
the simultaneous effect of several different explanatory variables
on risk of death in CF. To avoid any linearity assumptions in the
final logistic regressionmodel FEV1 Z score andBMI Z score were
dicotomised into an FEV1 Z score of b−2 SD below the mean
compared to an FEV1 Z score of≥−2 SD below the mean; a BMI
Z score b−1 SD below the mean, and a Z score≥−1 SD below the
mean. Significance was set at the 5% level. Data was analysed
using Epi-Info (CDC, Atlanta USA).
4. Results
At baseline there were 42 CFLD participants with CFLD
who were pair matched for age and sex with 42 participants
with CF but no evidence of liver disease (CF Controls). Seventy
two (85.7%) of the original 84 participants were available for
follow-up. Fig. 1 is a schematic representation of the outcome
Fig. 1. Event tree diagram showing those who have died and those still alive with CFLD in comparison with age and gender matched controls with CF but no
evidence of liver disease at two time points (7 and 10 years) after enrollment in the baseline study.
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characteristics of those with CFLD and CF Controls, together
with baseline characteristics of those who were alive (n = 53)
and those who have died (n = 19) at follow-up. There was no
difference in the age at baseline between participants with CFLD
and CF controls (Table 1). However there was a statistically
significant difference in the median age at follow-up between
those who died and those who were alive at follow-up (Table 1).Table 1
Baseline characteristics of participants.
Variable CFLD CF controls
N 36 36
Age at baseline (years) 13.9 (4.5) 14.0 (5.6)
aAge at follow-up (years) 21.7 (6.5) 23.6 (5.6)
Duration follow-up (years) 10.4 (2.6) 10.4 (0.1)
Age Diagnosis CF (Mths) 4.5 (22.5) 1.5 (5.5)
Birth weight (kg) 3.5 (0.6) 3.1 (1.4)
Height bZ score −0.9 (1.8) −0.8 (1.8)
Weight Z score −0.9 (2.0) −0.6 (3.1)
cBMI Z score −0.2 (0.7) −0.2 (0.9)
dFEV1 Z score −2.2 (2.5) −1.5 (4.3)
Albumin 40.0 (5.0) 41.0 (5.00)
Platelets 143.5 (138) 311.0 (97)
e,fUAFA b25th centile (n%) 19 (54.3) 11 (33.3)
Male (n%) 22 (61) 22 (61)
Baseline characteristics of participants with CFLD and CF controls (Column 2–4)
follow-up.
Data is presented as median with interquartile range or proportion.
a Age at follow-up in those who have died is age at death.
b Z Score = Standard deviation score.
c BMI = body mass index.
d FEV1 = forced expiratory volume in 1 sec.
e UAFA = upper arm fat mass.5. Mortality in CFLD
At the 10-year follow-up, 19 (26.38%) of 72 participants
had died or received an isolated organ transplant (liver = 2,
lung = 2) (Fig. 2). Participants with CFLD had a significantly
greater risk of mortality compared to CF controls with no
evidence of liver disease (14/36 (38.9%) compared to 5/36,
(13.9%); OR 3.94 95% CI 1.24–13.56 p = 0.01).p Dead Alive p
19 53
0.67 14.1 (3.9) 13.9 (5.2) 0.7
0.19 19.8 (3.5) 24.3 (5.2) 0.001
0.07 6.7 (3.7) 10.5 (0.1) 0.001
0.18 5.0 (22.5) 2.0 (9.5) 0.4
0.19 3.3 (0.6) 3.4 (1.1) 0.3
0.25 −1.1 (1.2) −0.9 (2.1) 0.4
0.19 −1.1 (1.6) −0.8 (0.7) 0.07
0.73 −0.8 (1.5) −0.2 (0.8) 0.04
0.05 −3.6 (2.6) −1.7 (2.1) 0.001
0.02 38.0 (8.00) 41.0 (5.0) 0.003
0.01 153.0 (285) 269.0 (128) 0.55
0.08 12 (66.7) 18 (36.0) 0.02
0.5 7 (36.8) 37 (69.8) 0.01
and baseline characteristics of those who have died or are alive after 10 years
Fig. 2. Kaplan Meier Plot showing the probability of survival in CF participants
with liver disease (CFLD Red Line) compared to CF Controls with no evidence
of liver disease (CF Controls Blue Line) (Log Rank Test p = 0.02).
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those who died with CFLD were female compared to 5 males
(Adjusted OR 5.77 95% CI 1.33–28.24 p = 0.015) Table 2. Of
the 5 controls who died 3 were female and 2 were male.
6. Risk factors for mortality
Participants who died or received a transplant (n = 19)
during the 10 year follow-up period had statistically signifi-
cant reduced measurements at baseline for BMI, UAFA and
pulmonary function compared to those who were still alive
(n = 53) (Table 1). Differences in albumin but not platelet
count were also apparent at baseline between those alive and
those who died over the subsequent 10 years.
In an exploratory logistic regression model nutritional param-
eters (BMI, height, weight, skin fold measurements) pulmonary
function and serum albumin and platelet count were entered as
continuous variables, while gender and liver disease were binary
variables (data not shown). In the final model pulmonary function
was dichotomised into those with milder disease (FEV1 %Table 2
Multiple logistic regression of the risk factors for mortality in CF.
Variable Outcome dead n Outcome alive n O
Liver disease Yes 14 22 3.
No 5 31
Gender Female 12 16 3.
Male 7 37
FEV1 Z score b−2 SD 15 23 4.
4 30
BMI Z score b−1SD 7 7 3.
12 46
Age at baseline
Univariate (*unadjusted odds ratio) and multivariate logistic regression analysis of tpredicted Z score ≥−2 SD below the mean) and those with
moderate to severe disease (FEV1 % predicted Z score b−2 SD
below the mean) at baseline. BMI was dichotomised as normal
BMI Z score ≥−1 SD below the mean, or low BMI Z score as
b−1 SD below the mean. Liver disease with portal hyperten-
sion, female gender, and moderate to severe lung disease (FEV1
Z score of b−2 SD below the mean) were all independent risk
factor for mortality in CF (Table 2). In this model a low BMI
(BMI Z score of b−1 SD below the mean) almost reached
statistical significance (OR 6.47 95% CI 0.96–43.26 p = 0.054).
7. Cause of death in participants with CFLD
Of the 14 participants with CFLD who died or received a
transplant (n = 2), 7 (50%) died from pulmonary causes, while
7 (50%) died from hepatic causes. There were no differences in
baseline data between those individuals with CFLD who died
and those who were still alive (data not shown).
All of the CF controls died from pulmonary complications
of CF. The controls with CF who died in this study (n = 5) had
much worse pulmonary function at baseline (median FEV1 %
predicted Z score −4.48 SD IQR 1.69) compared to controls
(n = 31) who were still alive (median FEV1 % predicted Z Score
−1.46 SD IQR 3.56 p = 0.001) and were shorter and lighter than
the controls who were still alive, suggesting that the controls with
CF who had died at follow-up were much sicker at baseline
compared to those who survived.
8. Comparison of those alive at 10 years
Twenty-two participants with CFLD were alive after 10 years.
Fifteen (68.18%) had clinical and radiological evidence of liver
disease with portal hypertension and hypersplenism at follow-up.
Of the 8 participants who were classified as “indeterminate” liver
disease at the 7 year follow-up because they had no definite
clinical evidence of portal hypertension, 6 remain “indeterminate.”
One of the 8 has died from pulmonary complications, and one
developed portal hypertension with varices. The participant who
has developed portal hypertension at 10 years was less than
10 years of age at baseline.
Of those who were still alive at 10 years there was no
difference in height, weight, or BMI between participants with
CFLD and CF controls. However, 11/22 (50%) of participants
with CFLD had cystic fibrosis related diabetes mellitus (CFRDM)dds ratio* 95% CI Adjusted odds ratio 95% CI p
9 1.2–12.6 4.3 1.1–17.2 0.04
9 1.3–11.9 12.2 2.4–63.2 0.01
8 1.4–18.8 5.1 1.1–23.8 0.04
7 1.1–13.4 6.5 0.96–43.3 0.054
1.1 0.8–1.3 0.4
he risk factors for mortality in participants with cystic fibrosis.
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(OR 4.04 95% CI 1.19–14.71 p = 0.02). At baseline only 3
participants with CFLD had evidence of impaired glucose
tolerance and one CF control, and none of the 4 was receiving
insulin at baseline.
9. Discussion
The outcome for individuals with CF has dramatically
improved over the last 20 years due to advances in the diagnosis
and management of CF particularly with the introduction of
newborn screening. While pulmonary complications remain the
main cause of morbidity and mortality in CF it is now important
to consider non-pulmonary complications of CF, such as liver
disease, to determine if survival can be further improved. We
have shown that CFLD represents a worse phenotype in CF [15].
Having now followed the original pair-matched cohort for
10 years we show that CFLD with portal hypertension is an
independent risk factor for mortality in CF. Participants in this
study with CFLD have almost 3 times the risk of death compared
to controls with CF but no evidence of liver disease in this study.
In keeping with previous clinical and research evidence [21–27]
we also found that female gender and poor pulmonary function
were independent risk factors for mortality in this study
population.
While poor nutrition is a significant risk factor for mortality
in CF, a BMI Z score b−1 SD failed to reach statistical sig-
nificance in this model (Table 2). However, BMI centile may
not reflect accurately the nutritional status in individuals with
portal hypertension as an enlarged spleen or possible ascites
may inflate the BMI measurement.
While there is conflicting evidence on the outcome for
individuals with CFLD and portal hypertension it is becoming
clearer that those with clinically significant liver disease represent
a worse phenotype in CF with reduced survival [13–15]. Most
studies to date, which have examined the outcome for patients
with CFLD have only considered liver-related deaths. However
we know from the literature that those with CFLD who survive
into adulthood have a relatively stable disease with few deaths
due to liver complications [8–10]. It is important to consider all
cause mortality and to include paediatric as well as adult patients.
The numbers in this study are relatively small but it comprises a
national cohort of well-characterised participants with CFLD and
their age and sex matched controls, thereby minimising potential
biases associated with single centre studies, such as differences
due to clinical practice or referral patterns. The follow-up period
spanned the transition into adult care, and the inclusion of all
cause mortality, rather thanmortality from hepatic causes alone is
important because not all individuals with CFLD will die from
hepatic causes [14]. Age and gender are significant risk factors
for mortality in CF and therefore choosing an appropriate
comparison group is essential in understanding the outcome for
CFLD. In this study participants were matched at baseline for age
and gender.
It is likely that our calculations underestimate the increased
mortality risk for those with CFLD. While this study was
strengthened by the inclusion of an appropriate age and sexmatched control group, an unintentional limitation arose from
the necessity to enrol participants during a routine hospital
visit. This was a condition of the Research Ethics Committees'
approval which stipulated that attendance over and above that
necessary for usual care was not permitted. Therefore, it is
likely that the controls in our study were not fully represen-
tative of the normal paediatric CF population in Ireland as they
were likely to be sicker and require more frequent hospital visits
than average. It is now clear that there were substantial differences
in pulmonary function and BMI at baseline between those control
patients who subsequently died and controls who were still alive.
In retrospect, it would also have been prudent to exclude controls
with an FEV1 in the moderate to severe range. However, despite
having enrolled a relatively sicker control group of patients with
CF, the mortality among those with CFLD was still 2.8 times
greater after a relatively short (10 year) follow-up.
As stated previously the diagnosis of portal hypertension in CF
liver disease is less than straight forward [2,4–6]. We excluded 5
participants in the CFLD group from follow-up because it was
determined on re-examination of their data that therewas inadequate
clinical or radiological data to support a diagnosis of portal
hypertension. Three controls were also excluded because their FEV1
was less than 30% predicted at baseline. An FEV1 of less than 30%
is not compatible with long-term survival [24] and would bias an
outcome or survival analysis in a long-term follow-up study. A
further 3 participants were lost to follow-up (1 with CFLD, 2
controls). In order to evaluate the impact of the exclusions and
losses to follow-up on our findings we re-analysed the data
classifying exclusions and losses to follow-up among cases and
controls as all dead or all alive. Regardless of categorisation,
participants at baseline with CFLD have a worse outcome
compared to controls with no evidence of CFLD.
Our data do not help address the important question of how
to identify those at risk of progressive liver disease with a
poorer outcome. While those with CFLD had worse pul-
monary function and nutritional parameters at baseline, there
were no factors which differentiated those who died with liver
disease from those who survived with liver disease. Almost
25% of children who had clinical or radiological evidence of
portal hypertension at baseline have not developed progres-
sive liver disease as adults with their liver disease following a
relatively benign course. However in the absence of invasive
procedures such as liver biopsy or portal pressure measure-
ments it is not possible to determine if these young adults
have any degree of portal hypertension after 10 years of
follow-up.
It is important to note the high proportion of CFLD
participants with diabetes mellitus requiring insulin therapy
compared to CF controls. At baseline no participant was
receiving insulin therapy, although 3 participants with CFLD
and 1 CF control had impaired glucose tolerance [16]. This
cannot be explained by the change in the diagnostic criteria or
management of CFRD since baseline, and it was unlikely that
there was any difference in the diagnosis and management of
CFRD between cases and controls in this national cohort.
Prospective studies of liver disease in CF which carefully
phenotype participants for both liver disease and diabetes are
125M. Rowland et al. / Journal of Cystic Fibrosis 14 (2015) 120–126required to determine the relative contribution of liver disease
and diabetes to reduced life expectancy in CF.
In conclusion, liver disease is an independent risk factor for
mortality in CF patients and females with liver disease may have
a poorer outcome than males with liver disease. Further studies
examining all cause mortality in CFLD are required to confirm
these findings.Abbreviations
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